2023年度

原著論文－英文

1. Yanai H, Adachi H, Hakoshima M, Iida S, Katsuyama H. A Possible Therapeutic Application of the Selective Inhibitor of Urate Transporter 1, Dotinurad, for Metabolic Syndrome, Chronic Kidney Disease, and Cardiovascular Disease. Cells. 2024；4;13：5:450.
2. Yanai H, Adachi H, Hakoshima M, Katsuyama H. A Possible Exquisite Crosstalk of Urate Transporter 1 With Other Urate Transporters for Chronic Kidney Disease and Cardiovascular Disease Induced by Dotinurad. Cardiol Res. 2023;14:2:158-160.
3. Miura Y, Tsuji Y, Yoshio T, Hatta W, Yabuuchi Y, Hoteya S, Kikuchi D, Tsuji S, Nagami Y, Hikichi T, Kobayashi M, Morita Y, Sumiyoshi T, Iguchi M, Tomida H, Inoue T, Mikami T, Hasatani K, Nishikawa J, Matsumura T, Nebiki H, Nakamatsu D, Ohnita K, Suzuki H, Ueyama H, Hayashi Y, Sugimoto M, Yamaguchi S, Michida T, Yada T, Asahina Y, Narasaka T, Kuribayashi S, Kiyotoki S, Mabe K, Masamune A, Fujishiro M. Association between perioperative management of antiplatelet agents and risk of post-endoscopic submucosal dissection bleeding in early gastric cancer: analysis of a nationwide multicenter study. Gastrointest Endosc. 2023;97:5:889-897.
4. Yanai H, Adachi H, Hakoshima M, Katsuyama H. Glucose-Lowering Effects of Imeglimin and Its Possible Beneficial Effects on Diabetic Complications. .Biology (Basel); 2023;12:5:726.
5. Yanai H, Adachi H, Hakoshima M, Katsuyama H. Significance of Endothelial Dysfunction Amelioration for Sodium-Glucose Cotransporter 2 Inhibitor-Induced Improvements in Heart Failure and Chronic Kidney Disease in Diabetic Patients. Metabolites. 2023;13:6:736.
6. Hamasaki H, Yanai H. Association of the use of psychotropic drugs with hospitalization, cardiovascular events, and mortality in patients with type 2 diabetes: a propensity score-matched cohort study. Front Clin Diabetes Healthc. 2023;4:1181998.
7. Katsuyama H, Yanai H, Adachi H, Hakoshima M. A Significant Effect of Pemafibrate on Hepatic Steatosis and Fibrosis Indexes in Patients With Hypertriglyceridemia. Gastroenterology Res. 2023;16:4:240-243.
8. Katsuyama H, Hakoshima M, Adachi H, Yanai H. The real-world efficacy of pemafibrate on metabolic-associated fatty liver disease (MAFLD): A one-year retrospective study. Atherosclerosis 2023; 379: 117162.
9. Yanai H, Adachi H, Hakoshima M, Katsuyama H. Postprandial Hyperlipidemia: Its Pathophysiology, Diagnosis, Atherogenesis, and Treatments. Int J Mol Sci. 2023 Sep 11;24(18):13942.
10. Yanai H, Yoshikawa R. A significant association of routine chest computed tomography-measured pericardial fat area with coronary risk factors and coronary artery disease. Atherosclerosis 2023; 379:1:S47.
11. Yanai H, Adachi H, Hakoshima M, Iida S, Katsuyama H. Metabolic-Dysfunction-Associated Steatotic Liver Disease-Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments. Int J Mol Sci. 2023;24:20:15473.
12. Ito R, Manita D, Yanai H, Hirowatari Y. Measurement of cholesterol levels of lipoprotein subclasses in human serum using anion-exchange high-performance liquid chromatography with a linear concentration gradient of sodium perchlorate. Ann Clin Biochem. 2023;60:6:374-385.
13. Yanai H, Adachi H, Hakoshima M, Katsuyama H. The Safety of Sodium Glucose Cotransporter 2 Inhibitors for the Elderly Diabetic Patients. J Endocrinol Metab. 2023;13:4:170-173
14. Kawasaki E, Awata T, Ikegami H, Imagawa A, Oikawa Y, Osawa H, Katsuki T, Kanatsuna N, Kawamura R, Kozawa J, Kodani N, Kobayashi T, Shimada A, Shimoda M, Takahashi K, Chujo D, Tsujimoto T, Tsuchiya K, Terakawa A, Terasaki J, Nagasawa K, Noso S, Fukui T, Horie I, Yasuda K, Yasuda H, Yanai H, Hanafusa T, Kajio H; Japanese Type 1 Diabetes Database Study (TIDE‐J). Prediction of future insulin-deficiency in glutamic acid decarboxylase autoantibody enzyme-linked immunosorbent assay-positive patients with slowly-progressive type 1 diabetes. J Diabetes Investig. 2024;15:7:835-842.
15. Okamura T, Tsukamoto K, Arai H, Fujioka Y, Ishigaki Y, Koba S, Ohmura H, Shoji T, Yokote K, Yoshida H, Yoshida M, Deguchi J, Dobashi K, Fujiyoshi A, Hamaguchi H, Hara M, Harada-Shiba M, Hirata T, Iida M, Ikeda Y, Ishibashi S, Kanda H, Kihara S, Kitagawa K, Kodama S, Koseki M, Maezawa Y, Masuda D, Miida T, Miyamoto Y, Nishimura R, Node K, Noguchi M, Ohishi M, Saito I, Sawada S, Sone H, Takemoto M, Wakatsuki A, Yanai H. Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2022. J Atheroscler Thromb. 2024;31:6:641-853.
16. Yanai H, Yoshinobu M, Adachi H. A Significance of Selective Inhibition of Urate Transporter 1 and Non-Inhibition of Adenosine Triphosphate-Binding Cassette Transporter in Renal Function in a Patient With Advanced Stage Chronic Kidney Disease. J Endocrinol Metab. 2024;14:2:85-88.
17. Yanai H, Adachi H, Hakoshima M, Katsuyama H. Significance of Endothelial Dysfunction Amelioration for Sodium-Glucose Cotransporter 2 Inhibitor-Induced Improvements in Heart Failure and Chronic Kidney Disease in Diabetic Patients. Metabolites. 2023 Jun 8;13(6):736.

口頭・ポスター発表－国際学会・研究会

1. Yanai H, Reo Yoshikawa.
   A Significant Association of Routine Chest Computed Tomography-Measured Pericardial Fat Area with Coronary Risk Factors and Coronary Artery Disease.
   91st Congress of the European Atherosclerosis Society. Mannheim, Germany, May, 2023.

2. Katsuyama H, Hakoshima M, Adachi H, Yanai H.
   The Real-World Efficacy of Pemafibrate on Metabolic-Associated Fatty Liver
   Disease (MAFLD): A One-Year Retrospective Study.
   91^st Congress of the European Atherosclerosis Society. Mannheim, Germany, May, 2023.

3. Hakoshima M, Katsuyama H, Adachi H, Yanai H.
   Pemafibrate Prevents the Progression of Nonalcholic Fatty Liver Disease in Patients with Hypertriglycemia: A One-Year Longitudinal Study.
   16th Congress of Asian Pacific Society of Atherosclerosis & Vascular Diseases. Kuala Lumpur, Malaysia, Sep, 2023.

口頭・ポスター発表－国内学会・研究会

1. 勝山 修行, 箱島 真理子, 梅山 翔平, 飯田 さくら, 足立 洋希, 柳内 秀勝.
   GLP-1受容体作動薬デュラグルチドの代謝パラメータへの影響に関する後ろ向き観察研究.
   第120回 日本内科学会総会・講演会, 東京, 4月, 2023.

2. 足立 洋希, 箱島 真理子, 勝山 修行, 柳内 秀勝.
   肝細胞癌患者のABO血液型による各種パラメーターや予後の検討.
   第66回日本糖尿病学会年次学術集会, 鹿児島, 5月, 2023.

3. 山口 尚紀, 勝山 修行, 箱島 真理子, 足立 洋希, 柳内 秀勝.
   SGLT2阻害薬の代謝パラメータに対する長期的効果についての後ろ向き観察研究.
   第66回日本糖尿病学会年次学術集会, 鹿児島, 5月, 2023.

4. 箱島 真理子, 足立 洋希, 勝山 修行, 柳内 秀勝.
   頸動脈超音波検査による動脈硬化指標と糖尿病・動脈硬化疾患との関連についての横断的観察研究.
   第66回日本糖尿病学会年次学術集会, 鹿児島, 5月, 2023.

5. 堀中 誠一, 勝山 修行, 箱島 真理子, 足立 洋希, 柳内 秀勝.
   日本人2型糖尿病患者における経口セマグルチドの心血管危険因子への効果に関する後ろ向き観察研究.
   第66回日本糖尿病学会年次学術集会, 鹿児島, 5月, 2023.

6. 雨宮 笑歌, 勝山 修行, 箱島 真理子, 足立 洋希, 柳内 秀勝.
   日本人2型糖尿病患者における持続性GLP-1受容体作動薬セマグルチド注射薬の多面的代謝改善効果　診療録を用いた後ろ向き観察研究
   第66回日本糖尿病学会年次学術集会, 鹿児島, 5月, 2023.

7. 勝山 修行, 山口 尚紀, 箱島 真理子, 足立 洋希, 柳内 秀勝.
   1型糖尿病におけるSGLT2阻害薬の効果の解析
   第96回 日本内分泌学会学術総会, 名古屋, 6月, 2023.

8. 山口 尚紀, 箱島 真理子, 勝山 修行, 足立 洋希, 柳内 秀勝
   SARS CoV-2ワクチン接種後に発症したギラン・バレー症候群で経過観察中にACTH単独欠損症が判明した一例.
   第24回日本内分泌学会 関東甲信越支部学術集会, 東京, 9月, 2023.

9. 柳内 秀勝.
   糖尿病患者に対する糖代謝異常・脂質代謝異常に関する臨床検査　食後高脂血症　病態・診断・その動脈硬化惹起性.
   第63回日本臨床化学会年次学術集会, 東京, 10月, 2023.

単行本－和文

1. 勝山　修行.
   入浴習慣と健康.
   日本温泉物理気候医学会編. 最新温泉医学, p352-353, 2023.

総説－和文

1. 柳内 秀勝, 濱崎 秀崇.【肥満と機能性食品】肥満治療標的としてのNon-exercise activity thermogenesis(NEAT).
   機能性食品と薬理栄養(1348-2564)16巻4号 Page226-231(2023.02)